Clinical Handbook of Psychotropic Drugs

Quick and comprehensive information on psychotropic drugs for adults.
Accurate and up-to-date
Comparison charts help decision-making
Icons with full color
Available both in print and online
Downloadable patient information sheets
More about this book
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
Independent, unbiased, up-to-date
Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
Potential interactions and side effects summarized in comparison charts
With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition
Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion)
Antipsychotics updates include revised clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
Dementia chapter includes a new section on lecanemab, a new fast-track FDA-approved treatment for Alzheimer's disease
Treatment of Substance Use Disorders includes revisions to buprenorphine dosing section that include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetics chapters all substantially revised
New formulations and trade names include: Auvelity (dextromethorphan/bupropion extended-release tablets), Invega Hafyera (paliperidone 6-monthly IM injection), Leqembi (lecanemab infusion), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)